- Home
- ICU vs CYCN Comparison
ICU vs CYCN Comparison
Compare ICU & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICU | CYCN |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 16.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ICU | CYCN |
|---|---|---|
| Price | $3.18 | $4.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.6K | 29.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | $1,234,000.00 | ★ $2,074,000.00 |
| Revenue This Year | $53.00 | N/A |
| Revenue Next Year | $50.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 814.07 | 3.70 |
| 52 Week Low | $0.22 | $1.03 |
| 52 Week High | $5.38 | $8.48 |
Technical Indicators
Market Signals| Indicator | ICU | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 60.09 |
| Support Level | $2.21 | $2.93 |
| Resistance Level | $4.96 | $3.97 |
| Average True Range (ATR) | 0.22 | 0.36 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 23.46 | 52.95 |
Price Performance
Historical ComparisonAbout ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.